Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT07590882
Enrolling by invitation Observational

Evaluation of Return to Sports Activity After Periacetabular Osteotomy: An Observational Study

NCT07590882 · tracked via the Priya Life Science Italy tracker
Sponsor
Istituto Ortopedico Rizzoli
Phase
Observational
Started
2025-11-04
Last updated
2026-05-15

Condition(s) studied

Hip SurgeriesHip Developmental Dysplasia

Investigational drug(s) / intervention(s)

Correction Factor

Correction Factor: periacetabular osteotomy

Study summary

This study aims to collect datas about patient who underwent periacetabular osteotomy

Eligibility

Sex
ALL
Min age
12 Years
Max age
40 Years
Healthy volunteers
No
Inclusion Criteria: * Patients of both sexes who underwent periacetabular osteotomy (PAO) at the sites of the Istituto Ortopedico Rizzoli (IOR) in Bologna (CORTI), Argenta, and Bagheria between 2017 and March 2025 * Postoperative follow-up ≥ 6 months * Complete clinical and radiographic documentation available for retrospective analysis * Willingness to participate in the study * Age at the time of surgery between 12 and 40 years Exclusion Criteria: * Patients unable to provide informed consent, unable to understand and decide, or minors whose parents/legal guardians do not provide informed consent * Patients with previous or ongoing oncological diseases, if associated with a potential impact on joint function or bone healing

Primary outcome measure(s)

  • return to sport — follow-up of 6 months
    The percentage of patients who return to their preoperative sports activity

Trial sites (1)

FacilityCityRegionStatus
IRCCS Istituto Ortopedico Rizzoli Bologna Italy

More Istituto Ortopedico Rizzoli trials in Italy

Clinical and Radiological Results of Long Term Tibial and Femoral Osteotomy in Knee Ostheoarthritis With Concomitant Lower Limb Malalignement Recruiting
Assessment of Periprosthetic Bone Mineral Density in Patients Undergoing Total Knee Prosthesis of Different Design Recruiting
Combined Use of PRP and Hyaluronic Acid for Infiltrative Treatment of Patients With Knee Osteoarthritis Recruiting
Identification of Circulating Biomarkers Associated With Extracellular Vesicles in Sarcomas Recruiting
Prospective Observational Cohort Study of Cardiac Structure and Function in Children and Adults With Osteogenesis Imperfecta Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07590882 on ClinicalTrials.gov ↗ ← All trials in Italy